Drugs / Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00923351 | Jun 2007 → Aug 2012 | alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, neuroblastoma, peripheral primitive neuroectodermal tumor | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00923351 ↗ |
| Modality | Vaccine | “experimental vaccine made from proteins from the patient's tumor cells” NCT00923351 ↗ |
| Route | Subcutaneous | “three intradermal (like a (tuberculosis) TB test) on one arm or leg and three subcutaneous (like those for insulin injections for diabetes). on the other arm or leg” NCT00923351 ↗ |